Caracterización de la expresión de proteínas relacionadas con mutaciones somáticas de significado pronóstico en Síndrome Mielodisplásico en biopsia de médula ósea de pacientes con citopenia en el Hospital Universitario Nacional de Colombia entre 2017 y 2022
dc.contributor.advisor | Franco-Tavera, Oscar Andres | spa |
dc.contributor.author | Cataño-Pulgarin, Juan Camilo | spa |
dc.contributor.orcid | Cataño Pulgarin, Juan Camilo [0000000318345624] | spa |
dc.coverage.city | Bogotá | spa |
dc.coverage.country | Colombia | spa |
dc.coverage.temporal | 2017-2022 | spa |
dc.date.accessioned | 2024-11-07T18:15:23Z | |
dc.date.available | 2024-11-07T18:15:23Z | |
dc.date.issued | 2024 | |
dc.description | ilustraciones, diagramas, tablas | spa |
dc.description.abstract | Introducción. Los Síndromes Mielodisplásicos son desórdenes clonales de las células hematopoyéticas definidos por citopenia, displasia mieloide y anormalidades genéticas características. La inclusión de las mutaciones somáticas es útil en el abordaje pronóstico y la inmunohistoquímica se ha explorado como marcador indirecto de estas. Objetivo. Caracterizar en términos de frecuencia relativa, patrón e intensidad de tinción las proteínas P53, EZH2 y H3K27me3 en biopsia de médula ósea de pacientes con síndrome mielodisplásico. Métodos. Estudio observacional, analítico de corte transversal en pacientes con síndrome mielodisplásico atendidos en el Hospital Universitario Nacional de Colombia entre 2017 y 2022. Se estudió la expresión de los marcadores P53, EZH2 y H3K27me3. Se empleó X2 o coeficiente de relación de Pearson para establecer asociaciones entre la expresión y variables de interés. Resultados y Conclusiones. Se practicaron los marcadores en 23 biopsias de médula ósea. Dos casos (5%) fueron positivos para TP53; los casos restantes fueron negativos. Todos los casos mostraron algún grado de tinción con EZH2 y H3K27me3 (exceptuando un caso negativo para EZH2). La expresión de EZH2 y H3K27me3 mostró una correlación positiva en el análisis de regresión lineal. La expresión de EZH2 y H3K27me3 no mostró asociación estadística con el conteo de plaquetas, neutrófilos, los valores de hemoglobina o el IPSS-R. La expresión de EZH2 no mostró asociación con cariotipo anormal, requerimiento transfusional o necesidad de tratamiento farmacológico. El establecimiento del estado de los genes EZH2 y TP53 permitirá determinar la implicación de la expresión de estas proteínas en el pronóstico de esta entidad (Texto tomado de la fuente). | spa |
dc.description.abstract | Introduction. Myelodysplastic Syndromes are clonal disorders of the hematopoietic cells, defined by the presence of cytopenia, dysplasia, and characteristic genetic abnormalities. Inclusion of somatic mutations is useful in the prognostic assessment and immunohistochemistry is an indirect way to detect the presence of these mutations. Objective. To characterize the relative frequency, stain pattern and stain intensity of P53, EZH2 and H3K27me3 by immunohistochemistry in bone marrow biopsies of patients with myelodysplastic syndrome. Methods. An observational, analytic cross-sectional study was conducted in patients with myelodysplastic syndrome at the Hospital Universitario Nacional de Colombia between 2017 and 2022. Immunohistochemistry for P53, EZH2 and H3K27me3 was studied. Pearson correlation coefficient or Chi-square tests were used to establish the association between the expression of these proteins and clinical variables of interest. Results and Conclusions: Twenty-three bone marrow biopsies were studied. Two cases (5%) were positive for p53. The rest of the cases were negative. All cases were positive for EZH2 and H3K27me3 (except for one case negative for EZH2). The expression of EZH2 and H3K27me3 were positively correlated in the linear regression analysis. The expression of EZH2 and H3K27me3 did not show association with platelet and neutrophil values, hemoglobin values or IPSS-R. The expression of EZH2 did not show association with abnormal karyotype, transfusions or requirement of pharmacological treatment. The assessment of the status of EZH2 and TP53 genes will allow us to establish the implication of the expression of these proteins in the prognostic assessment of myelodysplastic syndrome. | eng |
dc.description.degreelevel | Especialidades Médicas | spa |
dc.description.degreename | Especialista en Patología Anatómica y Clínica | spa |
dc.description.methods | Estudio observacional, analítico de corte transversal en pacientes con síndrome mielodisplásico atendidos en el Hospital Universitario Nacional de Colombia entre 2017 y 2022. Se estudió la expresión de los marcadores P53, EZH2 y H3K27me3. Se empleó X2 o coeficiente de relación de Pearson para establecer asociaciones entre la expresión y variables de interés. | spa |
dc.format.extent | 87 páginas | spa |
dc.format.mimetype | application/pdf | spa |
dc.identifier.instname | Universidad Nacional de Colombia | spa |
dc.identifier.reponame | Repositorio Institucional Universidad Nacional de Colombia | spa |
dc.identifier.repourl | https://repositorio.unal.edu.co/ | spa |
dc.identifier.uri | https://repositorio.unal.edu.co/handle/unal/87160 | |
dc.language.iso | spa | spa |
dc.publisher | Universidad Nacional de Colombia | spa |
dc.publisher.branch | Universidad Nacional de Colombia - Sede Bogotá | spa |
dc.publisher.faculty | Facultad de Medicina | spa |
dc.publisher.place | Bogotá, Colombia | spa |
dc.publisher.program | Bogotá - Medicina - Especialidad en Patología Anatómica y Clínica | spa |
dc.relation.references | Chan JKC, Jaffe ES KY-H. WHO classification of tumors of hematopoietic and lymphoid tissues (Revised 4th edition) IARC. WHO classification of tumors of hematopoietic and lymphoid tissues (Revised 4th edition) IARC. 2017. 353–4 p. | spa |
dc.relation.references | Hasserjian RP. Myelodysplastic Syndrome Updated. Pathobiology. 2019;86(1):53–61. | spa |
dc.relation.references | Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008;93(11):1712–7. | spa |
dc.relation.references | Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017;8(43):73483–500. | spa |
dc.relation.references | Chokr N, Pine AB, Bewersdorf JP, Shallis RM, Stahl M, Zeidan AM. Getting personal with myelodysplastic syndromes: is now the right time? Expert Rev Hematol [Internet]. 2019;12(4):215–24. Available from: https://doi.org/10.1080/17474086.2019.1592673 | spa |
dc.relation.references | Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical Effect of Point Mutations in Myelodysplastic Syndromes. N Engl J Med. 2011;364(26):2496–506. | spa |
dc.relation.references | Gondek LP, DeZern AE. Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states. Lancet Haematol [Internet]. 2020;7(1):e73–81. Available from: http://dx.doi.org/10.1016/S2352-3026(19)30211-X | spa |
dc.relation.references | Nazha A, Narkhede M, Radivoyevitch T, Seastone DJ, Patel BJ, Gerds AT, et al. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia. 2016;30(11):2214–20. | spa |
dc.relation.references | Carlos RE. Transición epidemiológica en Colombia: de las enfermedades infecciosas a las no transmisibles. Rev Ciencias Biomédicas. 2012;3(2). | spa |
dc.relation.references | Kawata E, Lazo-Langner A, Xenocostas A, Hsia CC, Howson-Jan K, Deotare U, et al. Clinical value of next-generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome. Br J Haematol. 2021;192(4):729–36. | spa |
dc.relation.references | Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Göhring G, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29(15):1971–9. | spa |
dc.relation.references | Saft L, Karimi M, Ghaderi M, Matolcsy A, Mufti GJ, Kulasekararaj A, et al. P53 Protein Expression Independently Predicts Outcome in Patients With Lower-Risk Myelodysplastic Syndromes With Del(5Q). Haematologica. 2014;99(6):1041–9. | spa |
dc.relation.references | Cleven AHG, Nardi V, Ok CY, Goswami M, Dal Cin P, Zheng Z, et al. High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Mod Pathol [Internet]. 2015;28(4):552–63. Available from: http://dx.doi.org/10.1038/modpathol.2014.153 | spa |
dc.relation.references | Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–88. | spa |
dc.relation.references | Fernandez-Pol S, Ma L, Ohgami RS, Arber DA. Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. Mod Pathol. 2016;29(9):996–1003. | spa |
dc.relation.references | Valent P, Bain BJ, Bennett JM, Wimazal F, Sperr WR, Mufti G, et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res [Internet]. 2012;36(1):1–5. Available from: http://dx.doi.org/10.1016/j.leukres.2011.08.016 | spa |
dc.relation.references | Jain M, Tripathi A. ICUS/CCUS/CHIP: basics & beyond. Expert Rev Hematol [Internet]. 2017;10(10):915–20. Available from: https://doi.org/10.1080/17474086.2017.1371588 | spa |
dc.relation.references | Steensma DP. The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS). Curr Hematol Malig Rep. 2019;14(6):536–42. | spa |
dc.relation.references | Mahmood R, Altaf C, Ahmed P, Khan SA, Malik HS. Myelodysplastic syndrome in Pakistan: Clinicohematological characteristics, cytogenetic profile, and risk stratification. Turkish J Hematol. 2018;35(2):109–15. | spa |
dc.relation.references | Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1–15. | spa |
dc.relation.references | Rodger EJ, Morison IM. Myelodysplastic syndrome in New Zealand and Australia. Intern Med J. 2012;42(11):1235–42. | spa |
dc.relation.references | Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: High number of uncaptured cases by cancer registries. Blood. 2011;117(26):7121–5. | spa |
dc.relation.references | Sweeney MR, Applebaum KM, Arem H, Braffett BH, Poynter JN, Robien K. Medical conditions and modifiable risk factors for myelodysplastic syndrome: A systematic review. Cancer Epidemiol Biomarkers Prev. 2019;28(9):1502–17. | spa |
dc.relation.references | Schnatter AR, Glass DC, Tang G, Irons RD, Rushton L. Myelodysplastic syndrome and benzene exposure among petroleum workers: An international pooled analysis. J Natl Cancer Inst. 2012;104(22):1724–37. | spa |
dc.relation.references | Link DC. Mechanisms of leukemic transformation in congenital neutropenia. Curr Opin Hematol. 2019;26(1):34–40. | spa |
dc.relation.references | Farrugia H, Wei A. Therapy-Related Acute Myeloid Leukaemia and Myelodysplastic Syndrome in Victoria, Australia 2003-2014. Intern Med J. 2018;48(7):822-829. | spa |
dc.relation.references | Candelaria M, Dueñas-Gonzalez A. Therapy-related myelodysplastic syndrome. Expert Opin Drug Saf. 2015;14(5):655–65. | spa |
dc.relation.references | Nagata Y, Maciejewski JP. The functional mechanisms of mutations in myelodysplastic syndrome. Leukemia [Internet]. 2019;33(12):2779–94. Available from: http://dx.doi.org/10.1038/s41375-019-0617-3 | spa |
dc.relation.references | Malcovati L, Cazzola M. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts. Br J Haematol. 2016;174(6):847–58. | spa |
dc.relation.references | Dan C, Chi J, Wang L. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy. Ann Med [Internet]. 2015;47(3):209–17. Available from: http://dx.doi.org/10.3109/07853890.2015.1009156 | spa |
dc.relation.references | Shallis RM, Ahmad R, Zeidan AM. The genetic and molecular pathogenesis of myelodysplastic syndromes. Eur J Haematol. 2018;101(3):260–71. | spa |
dc.relation.references | Meggendorfer M, Haferlach C, Kern W, Haferlach T. Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: A study on 123 patients and 27 genes. Haematologica. 2017;102(9):1502–10. | spa |
dc.relation.references | Epling-Burnette PK, List AF. Advancements in the molecular pathogenesis of myelodysplastic syndrome. Curr Opin Hematol. 2009;16(2):70–6. | spa |
dc.relation.references | Sundaravel S, Duggan R, Bhagat T, Ebenezer DL, Liu H, Yu Y, et al. Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes. Proc Natl Acad Sci U S A. 2015;112(46):E6359–68. | spa |
dc.relation.references | Freedman MH, Alter BP. Risk of myelodysplastic syndrome and acute myeloid leukemia in congenital neutropenias. Semin Hematol. 2002;39(2):128–33. | spa |
dc.relation.references | Frietsch JJ, Dornaus S, Neumann T, Scholl S, Schmidt V, Kunert C, et al. Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: Case series with focus on 5-azacytidine and literature review. Eur J Haematol. 2014;93(3):247–59. | spa |
dc.relation.references | Montoro J, Gallur L, Merchán B, Molero A, Roldán E, Martínez-Valle F, et al. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. Ann Hematol. 2018;97(8):1349–56. | spa |
dc.relation.references | Esatoglu SN, Hatemi G, Salihoglu A, Hatemi I, Soysal T, Celik AF, et al. A reappraisal of the association between Behçet’s disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review. Clin Exp Rheumatol . 2015 Nov-Dec;33(6 Suppl 94): S145-51. | spa |
dc.relation.references | Vijenthira A, Premkumar D, Callum J, Lin Y, Wells RA, Chodirker L, et al. The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study. Leuk Res [Internet]. 2019;76(September 2018):76–81. Available from: https://doi.org/10.1016/j.leukres.2018.12.002 | spa |
dc.relation.references | Li W, Morrone K, Kambhampati S, Will B, Steidl U, Verma A. Thrombocytopenia in MDS: Epidemiology, mechanisms, clinical consequences and novel therapeutic strategies. Leukemia. 2016;30(3):536–44. | spa |
dc.relation.references | Farah C, Bulai Livideanu C, Jegu J, Paul C, Viraben R, Lamant L, et al. Prevalence and prognostic value of cutaneous manifestations in patients with myelodysplastic syndrome. J Eur Acad Dermatology Venereol. 2010;24(10):1171–5. | spa |
dc.relation.references | Amin HM, Yang Y, Shen Y, Estey EH, Giles FJ, Pierce SA, et al. Having a higher blast percentage in circulation than bone marrow: Clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. Leukemia. 2005;19(9):1567–72. | spa |
dc.relation.references | Kayano H. Histopathology in the diagnosis of high-risk myelodysplastic syndromes. J Clin Exp Hematop. 2018;58(2):51–60. | spa |
dc.relation.references | Goasguen JE, Bennett JM, Bain BJ, Brunning R, Vallespi MT, Tomonaga M, et al. Dyserythropoiesis in the diagnosis of the myelodysplastic syndromes and other myeloid neoplasms: problem areas. Br J Haematol. 2018;182(4):526–33. | spa |
dc.relation.references | Liang C, Li J, Cheng J, Chen S, Ye Z, Zhang F, et al. Characteristics of bone marrow cell dysplasia and its effectiveness in diagnosing myelodysplastic syndrome. Hematology [Internet]. 2018;23(2):65–76. Available from: https://doi.org/10.1080/10245332.2017.1347247 | spa |
dc.relation.references | Schemenau J, Baldus S, Anlauf M, Reinecke P, Braunstein S, Blum S, et al. Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes. Eur J Haematol. 2015;95(3):181–9. | spa |
dc.relation.references | Matsushima T, Handa H, Yokohama A, Nagasaki J, Koiso H, Kin Y, et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood. 2003;101(9):3386–90. | spa |
dc.relation.references | Durrani J, Maciejewski JP. Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome. Hematol (United States). 2019;2019(1):97–104. | spa |
dc.relation.references | Nakanishi R, Ishida M, Hodohara K, Yoshida T, Yoshii M, Okuno H, et al. Prominent gelatinous bone marrow transformation presenting prior to myelodysplastic syndrome: A case report with review of the literature. Int J Clin Exp Pathol. 2013;6(8):1677–82. | spa |
dc.relation.references | Takahashi M, Koike T, Nagayama R, Fujiwara M, Koyama S, Ohnishi M, et al. Myelodysplastic syndrome with myelofibrosis: myelodysplastic syndrome as a major primary disorder for acute myelofibrosis. Clin Lab Haematol. 1991;13(1):17–23. | spa |
dc.relation.references | Malcovati L, Della Porta MG, Lunghi M, Pascutto C, Vanelli L, Travaglino E, et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2005;19(5):776–83. | spa |
dc.relation.references | Della Porta MG, Malcovati L, Invernizzi R, Travaglino E, Pascutto C, Maffioli M, et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2006;20(4):549–55. | spa |
dc.relation.references | Porwit A, Van De Loosdrecht AA, Bettelheim P, Eidenschink Brodersen L, Burbury K, Cremers E, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes - Proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia. 2014;28(9):1793–8. | spa |
dc.relation.references | Goardon N, Nikolousis E, Sternberg A, Chu WK, Craddock C, Richardson P, et al. Reduced CD38 expression on CD34 + cells as a diagnostic test in myelodysplastic syndromes. Haematologica. 2009;94(8):1160–3. | spa |
dc.relation.references | Alayed K, Meyerson JB, Osei ES, Blidaru G, Schlegelmilch J, Johnson M, et al. CD177 Enhances the Detection of Myelodysplastic Syndrome by Flow Cytometry. Am J Clin Pathol. 2020;153(4):554–65. | spa |
dc.relation.references | Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820–9. | spa |
dc.relation.references | De Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: Recommendations from an international expert panel. Blood. 2017;129(13):1753–62. | spa |
dc.relation.references | Baidoun F, Chen D, Patnaik M, Gangat N, Begna K, Elliott M, et al. Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. Leuk Lymphoma. 2019;60(10):2483–7. | spa |
dc.relation.references | Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65. | spa |
dc.relation.references | Scalzulli E, Pepe S, Colafigli G, Breccia M. Therapeutic strategies in low and high-risk MDS: What does the future have to offer? Blood Rev. 2021;45. | spa |
dc.relation.references | Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J [Internet]. 2018;8(5). Available from: http://dx.doi.org/10.1038/s41408-018-0085-4 | spa |
dc.relation.references | Kröger N, Brand R, Van Biezen A, Zander A, Dierlamm J, Niederwieser D, et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica. 2009;94(4):542–9. | spa |
dc.relation.references | Marisavljevic D, Savic A, Zeremski V, Stanisavljevic N, Jelic S. Myelodysplastic syndromes in adults aged less than 50 years: Incidence and clinicopathological data. J BUON. 2014;19(4):999–1005. | spa |
dc.relation.references | Wang F, Ni J, Wu L, Wang Y, He B, Yu D. Gender disparity in the survival of patients with primary myelodysplastic syndrome. J Cancer. 2019;10(5):1325–32. | spa |
dc.relation.references | Breccia M, Federico V, Latagliata R, Mercanti C, D’Elia GM, Cannella L, et al. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. Leuk Res. 2011;35(2):159–62. | spa |
dc.relation.references | Falantes JF, Márquez-Malaver FJ, Knight T, Calderón-Cabrera C, Martino ML, González J, et al. The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome*. Leuk Lymphoma. 2017;58(8):1893–902. | spa |
dc.relation.references | Sevindik OG, Guc Z, Kahraman S, Medeni Solmaz S, Katgi A, Acar C, et al. Hypoalbuminemia is a surrogate biomarker of poor prognosis in myelodysplastic syndrome even when adjusting for comorbidities. Leuk Lymphoma. 2015;56(9):2552–5. | spa |
dc.relation.references | Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol. 2013;160(5):660–72. | spa |
dc.relation.references | Hou HA, Tsai CH, Lin CC, Chou WC, Kuo YY, Liu CY, et al. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. Blood Cancer J [Internet]. 2018;8(4). Available from: http://dx.doi.org/10.1038/s41408-018-0074-7 | spa |
dc.relation.references | Gu S, Xia J, Tian Y, Zi J, Ge Z. A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS. BMC Cancer. 2021;21(1):1–9. | spa |
dc.relation.references | Kitagawa M, Yoshida S, Kuwata T, Tanizawa T, Kamiyama R. p53 Expression in myeloid cells of myelodysplastic syndromes: Association with evolution of overt leukemia. Am J Pathol. 1994;145(2):338–44. | spa |
dc.relation.references | McGraw KL, Nguyen J, Al Ali NH, Komrokji RS, Sallman D, Zhang X, et al. Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes. Br J Haematol. 2019;184(3):450–5. | spa |
dc.relation.references | Stomper J, Meier R, Ma T, Pfeifer D, Ihorst G, Blagitko-Dorfs N, et al. Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients. Clin Epigenetics. 2021;13(1):1–14. | spa |
dc.relation.references | Sashida G, Oshima M, Iwama A. Deregulated Polycomb functions in myeloproliferative neoplasms. Int J Hematol [Internet]. 2019;110(2):170–8. Available from: http://dx.doi.org/10.1007/s12185-019-02600-6 | spa |
dc.relation.references | Pekmezci M, Cuevas-Ocampo AK, Perry A, Horvai AE. Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors. Mod Pathol [Internet]. 2017;30(12):1710–9. Available from: http://dx.doi.org/10.1038/modpathol.2017.97 | spa |
dc.relation.references | Kazley JM, Dicaprio MR. Soft tissue and bone tumors. Pocket Foot and Ankle Medicine and Surgery. 2018. | spa |
dc.relation.references | Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay N V., et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog. 2008;47(9):701–6. | spa |
dc.relation.references | Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011;118(24):6239–46. | spa |
dc.relation.references | Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126(2):233–41. | spa |
dc.relation.references | Kubasch AS, Fenaux P, Platzbecker U. Development of luspatercept to treat ineffective erythropoiesis. Blood Adv. 2021;5(5):1565–75. | spa |
dc.relation.references | Martín I, Navarro B, Serrano A, Villamón E, Calabuig M, Solano C, et al. Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. Ann Hematol. 2020;99(3):527–37. | spa |
dc.relation.references | Zhang Q, Haider M, Al Ali NH, Lancet JE, Epling-Burnette PK, List AF, et al. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes. Clin Lymphoma, Myeloma Leuk [Internet]. 2020;20(6):400-406.e2. Available from: https://doi.org/10.1016/j.clml.2019.12.023 | spa |
dc.relation.references | Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts . N Engl J Med. 2011;365(15):1384–95. | spa |
dc.relation.references | Dolatshad H, Pellagatti A, Liberante FG, Llorian M, Repapi E, Steeples V, et al. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes. Leukemia. 2016;30(12):2322–31. | spa |
dc.relation.references | Nikpour M, Scharenberg C, Liu A, Conte S, Karimi M, Mortera-Blanco T, et al. The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia. 2013;27(4):889–96. | spa |
dc.relation.references | Thol F, Kade S, Schlarmann C, Löffeld P, Morgan M, Krauter J, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012;119(15):3578–84. | spa |
dc.relation.references | Zheng X, Zhan Z, Naren D, Li J, Yan T, Gong Y. Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis. PLoS One. 2017;12(9):1–12. | spa |
dc.relation.references | Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SCW, Ramakrishnan A, et al. SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer Cell [Internet]. 2015;27(5):617–30. Available from: http://dx.doi.org/10.1016/j.ccell.2015.04.006 | spa |
dc.relation.references | Procedure E. Immunohistochemical staining of formalin-fixed paraffin embedded tissues Immunohistochemical staining of formalin-fixed paraffin embedded tissues. 2010;13:4–6. | spa |
dc.relation.references | Geisel T, Martin J, Schulze B, Schaefer R, Bach M, Virgin G, et al. An etiologic profile of anemia in 405 geriatric patients. Anemia. 2014;2014. | spa |
dc.relation.references | Bach V, Schruckmayer G, Sam I, Kemmler G, Stauder R. Prevalence and possible causes of anemia in the elderly: A cross-sectional analysis of a large European university hospital cohort. Clin Interv Aging. 2014;9:1187–96. | spa |
dc.relation.references | Zhou J, Zhou N, Liu Q, Xie ZP, Xu Y, Dai SC, et al. Prevalence of neutropenia in US residents: a population based analysis of NHANES 2011–2018. BMC Public Health. 2023;23(1):1–9. | spa |
dc.relation.references | Matthew M. Hsieh, James E. Everhart, Danita D. Byrd-Holt, et al. Prevalence of Neutropenia in the U.S. Population: Age, Sex, Smoking Status, and Ethnic Differences. Ann Intern Med. 2004;146(19):486–92. | spa |
dc.relation.references | Yassin MA, Soliman AT, Hmissi SM, Abdulla MAJ, Itani M, Alamami AA, et al. Prevalence of neutropenia among adult Arabs in Qatar: Relation to other hematological parameters and anthropometric data. Med (United States). 2022;101(36):E30431. | spa |
dc.relation.references | Palmblad J, Siersma V, Lind B, Bjerrum OW, Hasselbalch H, Andersen CL. Age-related prevalence and clinical significance of neutropenia - isolated or combined with other cytopenias: Real world data from 373 820 primary care individuals. Am J Hematol. 2020;95(5):521–8. | spa |
dc.relation.references | Andersen CL, Tesfa D, Siersma VD, Sandholdt H, Hasselbalch H, Bjerrum OW, et al. Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: A longitudinal study. J Intern Med. 2016;279(6):566–75. | spa |
dc.relation.references | Agravat AH, Pujara K, Kothari RK, Dhruva GA. A clinico-pathological study of geriatric anemias. Aging Med. 2021;4(2):128–34. | spa |
dc.relation.references | Orces CH. Prevalence of Anemia among Older Adults Residing in the Coastal and Andes Mountains in Ecuador: Results of the SABE Survey. Curr Gerontol Geriatr Res. 2017;2017. | spa |
dc.relation.references | Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. Blood [Internet]. 2004;104(8):2263–8. Available from: http://dx.doi.org/10.1182/blood-2004-05-1812 | spa |
dc.relation.references | Michalak SS, Rupa-Matysek J, Hus I, Gil L. Unexplained anemia in the elderly - A real life analysis of 981 patients. Arch Med Sci. 2020;16(4):834–41. | spa |
dc.relation.references | Alsaeed M, Ahmed SS, Seyadi K, Ahmed AJ, Alawi AS, Abulsaad K. The prevalence and impact of anemia in hospitalized older adults: A single center experience from Bahrain. J Taibah Univ Med Sci [Internet]. 2022;17(4):587–95. Available from: https://doi.org/10.1016/j.jtumed.2022.02.003 | spa |
dc.relation.references | Singh A, Hungund B, Kumar L, Pattanshetti M. Clinico-haematological profile of patients with bicytopenia. Pathology. 2018;50(5):540–8. | spa |
dc.relation.references | Nell EM, Chapanduka ZC. Aetiology of pancytopenia: Experience of a South African tertiary academic centre. Afr J Lab Med. 2022;11(1):1–8. | spa |
dc.relation.references | N. GB, Rao KS. Pancytopenia: A Clinico Hematological Study. J Lab Physicians. 2011;3(01):015–20. | spa |
dc.relation.references | Jain A, Garg R, Kaur R, Nibhoria S, Chawla SPS, Kaur S. Clinico-hematological profile of pancytopenic adult patients in a tertiary care teaching hospital. Tzu Chi Med J. 2022;34(1):95–101. | spa |
dc.relation.references | Vargas-Carretero CJ, Fernandez-Vargas OE, Ron-Magaña AL, Padilla-Ortega JA, Ron-Guerrero CS, Barrera-Chairez E. Etiology and clinico-hematological profile of pancytopenia: experience of a Mexican Tertiary Care Center and review of the literature. Hematol (United Kingdom). 2019;24(1):399–404. | spa |
dc.relation.references | Doshi D, Shah AN, Somani S, Jain A, Jivarajani H, Kothari P. Study of clinical and aetiological profile of 100 patients of pancytopenia at a tertiary care centre in India. Hematology. 2012;17(2):100–5. | spa |
dc.relation.references | Papadaki HA, Palmblad J, Eliopoulos GD. Non-immune chronic idiopathic neutropenia of adult: An overview. Eur J Haematol. 2001;67(1):35–44. | spa |
dc.relation.references | Tsaknakis G, Gallì A, Papadakis S, Kanellou P, Elena C, Todisco G, et al. Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia. Blood. 2021;138(14):1249–57. | spa |
dc.relation.references | McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, et al. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica 2016; 101:e320. | spa |
dc.relation.references | Ruzinova MB, Lee YS, Duncavage EJ, Welch JS. TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies. Haematologica 2019; 104:e345 | spa |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.rights.license | Atribución-NoComercial 4.0 Internacional | spa |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | spa |
dc.subject.ddc | 610 - Medicina y salud::616 - Enfermedades | spa |
dc.subject.ddc | 610 - Medicina y salud::615 - Farmacología y terapéutica | spa |
dc.subject.decs | Examen de la Médula Ósea | spa |
dc.subject.decs | Bone Marrow Examination | eng |
dc.subject.decs | Células Madre Hematopoyéticas | spa |
dc.subject.decs | Hematopoietic Stem Cells | eng |
dc.subject.decs | Hematopoyesis Clonal | spa |
dc.subject.decs | Clonal Hematopoiesis | eng |
dc.subject.decs | Citopenia | spa |
dc.subject.decs | Cytopenia | eng |
dc.subject.decs | Inmunohistoquímica | spa |
dc.subject.decs | Immunohistochemistry | eng |
dc.subject.proposal | Myelodysplastic Syndromes | eng |
dc.subject.proposal | Immunohistochemistry | eng |
dc.subject.proposal | Prognosis | eng |
dc.subject.proposal | Bone Marrow | eng |
dc.subject.proposal | Mutation | eng |
dc.subject.proposal | Síndrome Mielodisplásico | spa |
dc.subject.proposal | Inmunohistoquímica | spa |
dc.subject.proposal | Pronóstico | spa |
dc.subject.proposal | Médula Ósea | spa |
dc.subject.proposal | Myelodysplastic Neoplasms | eng |
dc.subject.proposal | Mutación | spa |
dc.subject.proposal | Neoplasia Mielodisplásica | spa |
dc.title | Caracterización de la expresión de proteínas relacionadas con mutaciones somáticas de significado pronóstico en Síndrome Mielodisplásico en biopsia de médula ósea de pacientes con citopenia en el Hospital Universitario Nacional de Colombia entre 2017 y 2022 | spa |
dc.title.translated | Characterization of the expression of proteins related to somatic mutations of prognostic significance in Myelodysplastic Syndrome in bone marrow biopsy of patients with cytopenia at the Hospital Universitario Nacional de Colombia between 2017 and 2022 | eng |
dc.type | Trabajo de grado - Especialidad Médica | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_bdcc | spa |
dc.type.coarversion | http://purl.org/coar/version/c_ab4af688f83e57aa | spa |
dc.type.content | Text | spa |
dc.type.driver | info:eu-repo/semantics/masterThesis | spa |
dc.type.redcol | http://purl.org/redcol/resource_type/TM | spa |
dc.type.version | info:eu-repo/semantics/acceptedVersion | spa |
dcterms.audience.professionaldevelopment | Estudiantes | spa |
dcterms.audience.professionaldevelopment | Investigadores | spa |
oaire.accessrights | http://purl.org/coar/access_right/c_abf2 | spa |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- 1030634874.2024.pdf
- Tamaño:
- 3.92 MB
- Formato:
- Adobe Portable Document Format
- Descripción:
- Tesis de Especialidad en Patología Anatómica y Clínica
Bloque de licencias
1 - 1 de 1
Cargando...
- Nombre:
- license.txt
- Tamaño:
- 5.74 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción: